01 / Contract Profile
75A50123C00050 Federal Contract Award
Agency code 7505
THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0001 2. EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 (BASE) THROUGH DECEMBER 31, 2029 3. ADD ACTIVITIES UNDER CLIN0002 AT NO ADDITIONAL COST TO THE GOVERNMENT 4. REV
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75A50123C00050 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations$24.87M
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2023 | $20.32M | 2 | — |
| FY 2024 | $0 | 3 | −100.0% |
| FY 2025 | $0 | 2 | — |
| FY 2026 | $24.87M | 3 | — |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | BARDA - ASPR / DAAPPO / BARDA DCMA |
05 / Contractor
Who holds this federal contract?
BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
UEI UA43HWRNXFS3 · CAGE SSU10
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $45.19M | 10 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AN13 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | $45.19M | 10 | 100.0% |
08 / Place of Performance
Where is the work recorded?
MALVERN, CHESTER, PENNSYLVANIA, UNITED STATES
ZIP 193551200
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Aug 4, 2026 | P00009 | $5.43M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| May 27, 2026 | P00008 | $13.31M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Feb 24, 2026 | P00007 | $6.13M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Sep 24, 2025 | P00006 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| May 7, 2025 | P00005 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Nov 25, 2024 | P00004 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Jun 28, 2024 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Jan 31, 2024 | P00002 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Nov 20, 2023 | P00001 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
| Sep 15, 2023 | Base action | $20.32M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AN13 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.